Elucidating the mechanisms by which disulfiram protects against obesity and metabolic syndrome
Michel Bernier, Dylan Harney, Yen Chin Koay, Antonio Diaz, Abhishek Singh, Devin Wahl, Tamara Pulpitel, Ahmed Ali, Vince Guiterrez, Sarah J Mitchell, Eun-Young Kim, John Mach, Nathan L Price, Miguel A Aon, David G LeCouteur, Victoria C Cogger, Carlos Fernandez-Hernando, John O'Sullivan, Mark Larance, Ana Maria Cuervo, Rafael de Cabo, Michel Bernier, Dylan Harney, Yen Chin Koay, Antonio Diaz, Abhishek Singh, Devin Wahl, Tamara Pulpitel, Ahmed Ali, Vince Guiterrez, Sarah J Mitchell, Eun-Young Kim, John Mach, Nathan L Price, Miguel A Aon, David G LeCouteur, Victoria C Cogger, Carlos Fernandez-Hernando, John O'Sullivan, Mark Larance, Ana Maria Cuervo, Rafael de Cabo
Abstract
There is an unmet need and urgency to find safe and effective anti-obesity interventions. Our recent study in mice fed on obesogenic diet found that treatment with the alcohol aversive drug disulfiram reduced feeding efficiency and led to a decrease in body weight and an increase in energy expenditure. The intervention with disulfiram improved glucose tolerance and insulin sensitivity, and mitigated metabolic dysfunctions in various organs through poorly defined mechanisms. Here, integrated analysis of transcriptomic and proteomic data from mouse and rat livers unveiled comparable signatures in response to disulfiram, revealing pathways associated with lipid and energy metabolism, redox, and detoxification. In cell culture, disulfiram was found to be a potent activator of autophagy, the malfunctioning of which has negative consequences on metabolic regulation. Thus, repurposing disulfiram may represent a potent strategy to combat obesity.
Keywords: Metabolic syndrome; Obesity.
Conflict of interest statement
Competing interestsThe authors declare no competing interests.
© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020.
Figures
References
- Khera R, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424–2434.
- Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74–86.
- Blundell JE, Gibbons C, Caudwell P, Finlayson G, Hopkins M. Appetite control and energy balance: impact of exercise. Obes. Rev. 2015;16(Suppl 1):67–76.
- Jacobs DR., Jr Fast food and sedentary lifestyle: a combination that leads to obesity. Am. J. Clin. Nutr. 2006;83:189–190.
- Cvek B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr. Cancer Drug Targets. 2011;11:332–337.
- Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 1992;175:1181–1194.
- Zhu T, Zhao R, Zhang L, Bernier M, Liu J. Pyrrolidine dithiocarbamate enhances hepatic glycogen synthesis and reduces FoxO1-mediated gene transcription in type 2 diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2012;302:E409–E416.
- Bernier M, et al. Disulfiram treatment normalizes body weight in obese mice. Cell Metab. 2020;S1550-4131:30236–30239.
- Pfuhlmann K, et al. Celastrol-induced weight loss is driven by hypophagia and independent from UCP1 (Erratum in: Diabetes 68, 676 (2018)). Diabetes. 2017;67:2456–2465.
- Quarta C, et al. Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity. Cell Metab. 2017;26:620–632.e6.
- Leshan RL, Bjornholm M, Munzberg H, Myers MG., Jr. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring) 2006;14:208S–212S.
- Paz-Filho G, Mastronardi C, Wong ML, Licinio J. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J. Endocrinol. Metab. 2012;16:S549–S555.
- Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell. 2015;161:999–1011.
- Chellappa K, Perron IJ, Naidoo N, Baur JA. The leptin sensitizer celastrol reduces age-associated obesity and modulates behavioral rhythms. Aging Cell. 2019;18:e12874.
- Mohamad M, et al. Ultrastructure of the liver microcirculation influences hepatic and systemic insulin activity and provides a mechanism for age-related insulin resistance. Aging Cell. 2016;15:706–715.
- Madrigal-Matute J, Cuervo AM. Regulation of liver metabolism by autophagy. Gastroenterology. 2016;150:328–339.
- Singh R, et al. Autophagy regulates lipid metabolism. Nature. 2009;458:1131–1135.
- Kaushik S, Cuervo AM. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat. Cell Biol. 2015;17:759–770.
- Koga H, Kaushik S, Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion. FASEB J. 2010;24:3052–3065.
- Rodriguez-Navarro JA, et al. Inhibitory effect of dietary lipids on chaperone-mediated autophagy. Proc. Natl Acad. Sci. USA. 2012;109:E705–E714.
- Christmas P. Role of cytochrome P450s in inflammation. Adv. Pharmacol. 2015;74:163–192.
- Wheatcroft SB, et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes. 2007;56:285–294.
- Heald AH, et al. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp. Clin. Endocrinol. Diabetes. 2006;114:371–376.
- Aoyagi T, et al. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148:2075–2084.
- Cantau B, Guillon G, Mathieu MN, Vidal-Chicot D, Chevillard C. Reduction in hepatic but not in renal and vascular vasopressin receptor number in hyperinsulinemic mice and rats. Mol. Cell. Endocrinol. 1984;38:131–139.
- Theken KN, et al. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am. J. Physiol. Endocrinol. Metab. 2012;302:E500–E509.
- Wang H, et al. Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol. Pharmacol. 2004;65:1148–1158.
- Zhou L, et al. Cidea promotes hepatic steatosis by sensing dietary fatty acids. Hepatology. 2012;56:95–107.
- Gong J, Sun Z, Li P. CIDE proteins and metabolic disorders. Curr. Opin. Lipidol. 2009;20:121–126.
- Cohen DE. New players on the metabolic stage: How do you like them acots? Adipocyte. 2013;2:3–6.
- Chen Y, et al. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. 2011;12:534–541.
- Qiu XL, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12:662–667.
- Chen Y, Azad MB, Gibson SB. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ. 2009;16:1040–1052.
- Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545–15550.
- Oxenkrug G. Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol. Neurobiol. 2013;48:294–301.
- Badawy AA, Banos S. Elevation of kynurenine metabolites in rat liver and serum: a potential additional mechanism of the alcohol aversive and anti-cancer effects of disulfiram? Alcohol Alcohol. 2016;51:20–26.
- González Esquivel D, et al. Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology. 2017;112:331–345.
- Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc. Natl Acad. Sci. USA. 2006;103:5805–5810.
- Sahu R, et al. Microautophagy of cytosolic proteins by late endosomes. Dev. Cell. 2011;20:131–139.
- Koga H, Martinez-Vicente M, Macian F, Verkhusha VV, Cuervo AM. A photoconvertible fluorescent reporter to track chaperone-mediated autophagy. Nat. Commun. 2011;2:386.
- Hernandez I, et al. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. Sci. Transl. Med. 2019;11:eaat3005.
- Hogarth G. Metal-dithiocarbamate complexes: chemistry and biological activity. Mini Rev. Med. Chem. 2012;12:1202–1215.
- Tamargo-Gómez I, Mariño G. AMPK: regulation of metabolic dynamics in the context of autophagy. Int. J. Mol. Sci. 2018;19:E3812.
- Dunlop EA, Tee AR. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin. Cell Dev. Biol. 2014;36:121–129.
- Song S, et al. Impact of pyrrolidine dithiocarbamate and interleukin-6 on mammalian target of rapamycin complex 1 regulation and global protein translation. J. Pharm. Exp. Ther. 2011;339:905–913.
- Poulsen HE, Jorgensen L, Thomsen P. Prevention of acetaminophen hepatotoxicity by disulfiram. Pharmacol. Ther. 1987;33:83.
- Emery MG, Jubert C, Thummel KE, Kharasch ED. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1enzyme half-life after single-dose disulfiram administration in humans. J. Pharmacol. Exp. Ther. 1999;291:213–219.
- Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br. J. Clin. Pharmacol. 2002;53:155–162.
- Daly AK. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metab. Pers. Ther. 2015;30:165–174.
- Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwa C. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin. Drug Metab. Toxicol. 2014;10:769–785.
- Cheadle C, Cho-Chung YS, Becker KG, Vawter MP. Application of z-score transformation to Affymetrix data. Appl. Bioinformatics. 2003;2:209–217.
- Lee JS, et al. Meta-analysis of gene expression in the mouse liver reveals biomarkers associated with inflammation increased early during aging. Mech. Ageing Dev. 2012;133:467–478.
- Kim SY, Volsky DJ. PAGE: parametric analysis of gene set enrichment. BMC Bioinforma. 2005;6:144.
- Hatchwell L, et al. Multi-omics analysis of the intermittent fasting response in mice identifies an unexpected role for HNF4α. Cell Rep. 2020;30:3566–3582.e4.
- Harney DJ, et al. Proteomic analysis of human plasma during intermittent fasting. J. Proteome Res. 2019;18:2228–2240.
- Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008;26:1367–1372.
- Cox J, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011;10:1794–1805.
- Cox J, et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteom. 2014;13:2513–2526.
- Mach J, et al. The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats. Fundam. Clin. Pharmacol. 2016;30:23–34.
- Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. first enzymatic step mercapturic acid formation. J. Biol. Chem. 1974;249:7130–7139.
- Kaushik S, Cuervo AM. Methods to monitor chaperone-mediated autophagy. Methods Enzymol. 2009;452:297–324.
- Auteri JS, Okada A, Bochaki V, Dice JF. Regulation of intracellular protein degradation in IMR- 90 human diploid fibroblasts. J. Cell. Physiol. 1983;115:159–166.
Source: PubMed